CTX310 Receives Two FDA RMAT Designations

Company CRISPR Therapeutics Event Type Regulatory designation (RMAT) and Q3 update (source-gap recovery) Modality In vivo LNP-delivered CRISPR liver editing Asset CTX310 Target ANGPTL3 Disease Area Severe hypertriglyceridemia; elevated LDL-C Summary In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA…